A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival

[1]  M. Schwaiger,et al.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. S. Lee,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2011 , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[3]  M. Schwaiger,et al.  Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study , 2008, Clinical Cancer Research.

[4]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[5]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[6]  K. Jung,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010 , 2013, Cancer research and treatment : official journal of Korean Cancer Association.

[7]  C. Zhou,et al.  Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy , 2012, Acta radiologica.

[8]  Hyunsoon Cho,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015 , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[9]  I. Choi,et al.  CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients , 2011, British Journal of Cancer.

[10]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[11]  Y. Nishimura,et al.  AN INTERIM ANALYSIS , 2005 .

[12]  T Yamamoto,et al.  Nicotine metabolism and CYP2A6 allele frequencies in Koreans. , 2001, Pharmacogenetics.

[13]  A. Hölscher,et al.  [18F]‐fluorodeoxyglucose‐positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer , 2010, Journal of surgical oncology.

[14]  K. Ryu,et al.  Randomized phase II trial of neoadjuvant vs. adjuvant docetaxel plus cisplatin in patients with locally advanced gastric carcinoma: An interim analysis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Becker,et al.  Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxirubicin, and cisplatinum , 2001, Cancer.

[16]  H. McLeod,et al.  Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations , 2006, Clinical pharmacology and therapeutics.

[17]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[18]  Kazuhiro Yoshida,et al.  Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer , 2014, Annals of Surgical Oncology.

[19]  J. Thigpen.  Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial , 2011 .

[20]  Woo Ick Yang,et al.  A randomized phase 2 study of docetaxel and S‐1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy , 2011, Cancer.

[21]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[22]  R. Langer,et al.  Proposal for a Multifactorial Prognostic Score That Accurately Classifies 3 Groups of Gastric Carcinoma Patients With Different Outcomes After Neoadjuvant Chemotherapy and Surgery , 2012, Annals of surgery.

[23]  H. K. Kim,et al.  Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma , 2008, British Journal of Cancer.

[24]  J. Ajani,et al.  Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Schlag,et al.  Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[27]  I. Choi,et al.  Prognostic Value of Preoperative Clinical Staging Assessed by Computed Tomography in Resectable Gastric Cancer Patients: A Viewpoint in the Era of Preoperative Treatment , 2010, Annals of surgery.

[28]  A. Bardia,et al.  Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  E. Chiorean.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012 .

[30]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[31]  貝田 勇介.  The CYP2A6[*]4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer , 2009 .

[32]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[33]  Kazuhiro Araki,et al.  CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1 , 2008, Cancer science.

[34]  S. Curley,et al.  Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Langer,et al.  Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer , 2011, Annals of Surgical Oncology.

[36]  A. Nashimoto,et al.  Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis , 2014, The British journal of surgery.

[37]  I. Choi,et al.  Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. , 2009, Pharmacogenomics.

[38]  I. Choi,et al.  Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer , 2008, Cancer.

[39]  J. Zaluski,et al.  Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  J. Ji,et al.  Neoadjuvant chemotherapy with FOLFOX: Improved outcomes in Chinese patients with locally advanced gastric cancer , 2012, Journal of surgical oncology.

[41]  O. Dworak,et al.  Pathological features of rectal cancer after preoperative radiochemotherapy , 1997, International Journal of Colorectal Disease.

[42]  Kazuhiro Yoshida,et al.  Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START) , 2013, Journal of Cancer Research and Clinical Oncology.

[43]  G. Lee,et al.  A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma , 2013, Cancer Chemotherapy and Pharmacology.

[44]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[45]  Laura H. Tang,et al.  Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer? , 2007, Annals of Surgical Oncology.

[46]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Japanese Gastric Cancer Association.  Japanese Classification of Gastric Carcinoma – 2nd English Edition – , 1998, Gastric Cancer.